Germany· DE-A57-0e92437efc9d02e6
Resorcin Smartpractice Europe
A resorcinol product containing resorcinol, registered in Germany by Smartpractice Europe Gmbh. The same ATC class is registered in 3 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Resorcinol is registered in 3 of 19 countries.
Countries holding a registration under ATC D10AX02 (resorcinol), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
Resorcinol · ATC D10AX02
3 / 19 countries
- Germany
- Japan
- United Kingdom
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Resorcinol
- Manufacturer
- Smartpractice Europe Gmbh
- Country
- Germany (DE)
- ATC code
- D10AX02
- ATC class
- Resorcinol
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for resorcinol.
Graded by severity as the source publishes them — 3 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Resorcinol · interactions on record
3 records
- 3 moderate
Most severe, free to view
- TretinoinD10AD01moderate
- AdapaleneD10AD03moderate
- TrifaroteneD10AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Resorcinol in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/94de91c0-a1c9-4783-8fc5-bdb99b463c7d GET /v1/drugs/94de91c0-a1c9-4783-8fc5-bdb99b463c7d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Cutaneous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Resorcinol",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about resorcinol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.